Abstract Library

#3976 Radiologic tumor border status can further stratify patients with pancreatic neuroendocrine tumor

Introduction: Recently, pattern-based classifications of the tumor border of pancreatic neuroendocrine tumor (PanNET) have been attempted by independent groups for patient stratification, which are only available in the post-operative setting.

Conference:

Presenting Author: Ahn B

Authors: Ahn B, Park H, Kim H, Hong S,

Keywords: pancreas, neuroendocrine tumor, pathologic tumor border, radiologic tumor border, survival, prognosis,

#3792 Validation of a single time-point estimates of 177Lu-PRRT absorbed doses and impact on patient management for 192 therapies

Introduction: Dosimetry calculation after 177Lu-DOTA-TATE Peptide Receptor Radionuclide Therapy (PRRT) enables to estimate radiation doses absorbed by normal organs and target lesions. Previously, we described a newly developed model to predict absorbed doses (ADs) from a single post-treatment study with good accuracy as compared to the standard multiple time-points protocol.

Conference:

Presenting Author:

Authors: Chicheportiche A, Krausz Y, Godefroy J, Gross D, Grozinsky-Glasberg S,

Keywords: PRRT, Dosimetry, SPECT/CT, Single time-point,

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#3411 Cannabinoids and the Endocannabinoid System as modulatory targets in neuroendocrine neoplasms (NENs) – Possible mechanisms and antitumor efficacy

Introduction: Patients with unresectable NENs are offered a variety of non-curable therapeutic options, which eventually fail due to drug resistance (DR). Increasing evidence suggest an anticancer trait of cannabinoids, via cellular pathways including mTOR, known to be associated with DR development. Still, limited data exist on the anti-cancer effects of cannabinoids in NENs.

Conference:

Presenting Author: Avniel-Polak S

Authors: Avniel-Polak S, Polak D, Oleinikov K, Gross D, Wald O,

Keywords: neuroendocrine neoplasm, cannabinoids, endocannabinoid system, cannabis extracts, everolimus,

#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience

Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hayes A, Smith K, Liu M, Jenkinson S, Grossman A,

Keywords: Neuroendocrine, Carcinoid, Merkel cell carcinoma, Human immunodeficiency virus, HIV, Prognosis,